Apixaban Reduces Intracranial Bleeding Risk Compared To Aspirin In Patients With Cryptogenic Stroke And Atrial Cardiopathy EvidenceTrial shows apixaban reduces intracranial bleeding risk versus aspirin in cryptogenic stroke patients

A multicenter randomized trial evaluated the safety profile of apixaban versus aspirin in patients with cryptogenic stroke who also presented with evidence of atrial cardiopathy. The study enrolled 1,015 participants and followed them for a mean duration of 1.8 years, with a standard deviation of 1.2 years. The primary objective focused on assessing the incidence of hemorrhage events across the treatment groups. Researchers specifically aimed to determine if apixaban offered a superior safety margin regarding bleeding risks compared to standard aspirin therapy.

The analysis revealed that 115 out of 1,015 patients experienced a total of 146 hemorrhage events during the observation period. While the overall rate of any hemorrhage was reported without a specific effect size, the data highlighted distinct differences when examining intracranial bleeding specifically. Apixaban resulted in significantly fewer intracranial hemorrhages than aspirin, indicating a meaningful clinical benefit in this high-risk population. The absolute number of events was not explicitly detailed for every sub-category, but the relative risk reduction was statistically robust.

For the primary outcome of intracranial hemorrhage, the incidence rate difference was calculated at -1.4%, with a 95% confidence interval ranging from -2.3% to -0.5%. This negative value confirms a decrease in bleeding events for the apixaban group. When analyzing the intention-to-treat population specifically, the incidence rate difference remained favorable at -1.0%, with a confidence interval of -1.8% to -0.2%. These consistent results across different analytical populations strengthen the evidence for the drug's efficacy in preventing severe intracranial bleeding.

Further safety assessments included symptomatic intracranial hemorrhage within a safety sample and the broader intention-to-treat cohort. Findings for symptomatic intracranial hemorrhage in the safety sample mirrored the primary results, showing an incidence rate difference of -1.1% with a confidence interval of -1.8% to -0.3%. In the intention-to-treat analysis for symptomatic events, the difference was -0.7%, though this did not reach statistical significance with a p-value of 0.11 and a confidence interval extending to 0.0%. Despite this nuance, the trend consistently favored apixaban.

Regarding non-intracranial bleeding, the risks for major non-intracranial hemorrhage, any major hemorrhage, and minor hemorrhage did not differ significantly between the two treatment arms. This balance is crucial for clinical decision-making, as it suggests that the reduction in intracranial bleeding did not come at the cost of increased systemic bleeding. Patients who permanently discontinued the study drug were appropriately censored in the safety sample analysis to maintain data integrity.

The study design, a randomized trial, provides strong evidence for the causal relationship between treatment assignment and bleeding outcomes. While funding sources and specific conflicts of interest were not reported, the multicenter nature of the trial enhances the generalizability of the findings. Clinicians managing patients with cryptogenic stroke and atrial cardiopathy should consider these safety data when selecting anticoagulation strategies. The results support the use of apixaban as a potentially safer alternative to aspirin for preventing intracranial hemorrhage in this specific demographic.